Clinical Trial

External Hypofractionated Radiotherapy With Simultaneous Integrated Boost in Early Breast Cancer Patients

Study acronym: ESIBIRE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective non randomized phase two trial evaluating the feasibility of a ten fraction accelerated hypofractionated radiotherapy schedule with simultaneous integrated boost risk adapted in patients undergoing breast conserving surgery for early breast cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-24.
Status change: Recruiting → Active, Not Recruiting 2025-07-22
Trial Details
NCT Number NCT06224244
Lead Sponsor Regina Elena Cancer Institute
Conditions Breast Neoplasms, Breast Cancer
Enrollment 180 participants
Start Date 2022-02-01
Primary Completion 2025-04-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-25